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Abstract Celiac disease is caused by intolerance to cereal
gluten proteins, and HLA-DQ molecules are involved in the
disease pathogenesis by presentation of gluten peptides to
CD4+ T cells. The α- or β-chain sharing HLA molecules
DQ2.5, DQ2.2, and DQ7.5 display different risks for the
disease. It was recently demonstrated that T cells of DQ2.5
and DQ2.2 patients recognize distinct sets of gluten epitopes,
suggesting that these two DQ2 variants select different
peptides for display. To explore whether this is the case, we
performed a comprehensive comparison of the endogenous
self-peptides bound to HLA-DQ molecules of B-
lymphoblastoid cell lines. Peptides were eluted from
affinity-purified HLA molecules of nine cell lines and sub-
jected to quadrupole orbitrap mass spectrometry and
MaxQuant software analysis. Altogether, 12,712 endogenous
peptides were identified at very different relative abundances.
Hierarchical clustering of normalized quantitative data dem-
onstrated significant differences in repertoires of peptides
between the three DQ variant molecules. The neural
network-based method, NNAlign, was used to identify
peptide-binding motifs. The binding motifs of DQ2.5 and
DQ7.5 concurred with previously established binding motifs.
The binding motif of DQ2.2 was strikingly different from that
of DQ2.5 with position P3 being a major anchor having a
preference for threonine and serine. This is notable as three
recently identified epitopes of gluten recognized by T cells of
DQ2.2 celiac patients harbor serine at position P3. This study
demonstrates that relative quantitative comparison of endog-
enous peptides sampled from our protein metabolism by HLA
molecules provides clues to understand HLA association with
disease.
Keywords Antigen presentation/processing . Bindingmotif .
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Introduction
Major histocompatibility complex (MHC) II molecules dis-
play peptides on the surface of professional antigen presenting
cells for presentation to CD4+ T cells (Germain 1994). The
peptides derive from proteolytically processed proteins, either
exogenous proteins taken up by endocytosis or from
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endogenous proteins made for export via the Golgi pathway.
This proteolysis is performed by cathepsins and other en-
zymes present in endosomes. In the same endosomal com-
partments, the MHC II molecules are loaded with these exog-
enously derived peptides by exchange of class II-associated
invariant chain (CLIP) peptides that have occupied the bind-
ing groove since assembly of the MHC II molecules in the
endoplasmic reticulum. Peptides that make stable peptide-
MHC complexes will accumulate on the cell surface. These
peptides are particularly prone to be recognized by T cells as
the amount of peptide-MHC complexes matters for T-cell
activation (Henrickson et al. 2008).
For many autoimmune diseases, MHC II genes are major
genetic susceptibility determinants (Lettre and Rioux 2008).
In keeping with this, presentation of antigenic peptides to
CD4+ T cells is inferred to be central in the pathogenesis of
these conditions. Celiac disease, a chronic inflammatory dis-
order of the small intestine caused by an inappropriate im-
mune response to dietary gluten proteins of wheat, rye, and
barley, is one of the diseases with the most marked HLA
association. There is a strong HLA association with DQ2.5
(DQA1*05:01, DQB1*02:01) and weaker associations with
DQ8 (DQA1*03, DQB1*03:02) and DQ2.2 (DQA1*02:01,
DQB1*02:02) (Sollid and Lie 2005). The very few patients,
who are not DQ2.5, DQ2.2, or DQ8, are almost all DQ7.5
(DQA1*05, DQB1*03:01) (Karell et al. 2003). Notably,
DQ2.5 shares the β-chain with DQ2.2 (with exception of
one residue difference at position 135 in the membrane prox-
imal domain) and the α-chain with DQ7.5. HLA-DQ mole-
cules predispose to celiac disease by presenting gluten pep-
tides to CD4+ Tcells (Lundin et al. 1993). A number of gluten
epitopes that are presented to T cells in the context of DQ2.5
or DQ8 have been characterized (Sollid et al. 2012) and work
is ongoing to define DQ2.2 restricted T-cell epitopes (Bodd
et al. 2012; Dorum et al. 2014). Initial analysis indicated that
the peptide-binding motifs of DQ2.5 and DQ2.2 are similar
(Johansen et al. 1996a; Johansen et al. 1996b; Stepniak et al.
2008; Vader et al. 2003; van de Wal et al. 1996; van de Wal
et al. 1997; Vartdal et al. 1996), albeit it was suggested that
proline at P3 is disfavored byDQ2.2, but not by DQ2.5 (Vader
et al. 2003), that serine and threonine is favored by DQ2.2 at
P3 (van deWal et al. 1997), and that there could be differences
in binding specificity at P6 (Johansen et al. 1996a). The recent
finding that gluten-reactive gut Tcells of DQ2.2 celiac disease
patients recognize epitopes, which are different from those of
DQ2.5 celiac disease patients, strongly indicate that these DQ
molecules do select different peptides for presentation (Bodd
et al. 2012).
Peptide analysis by mass spectrometry (MS) has made
huge advances in recent time due to improved sensitivity of
instruments and new software that allows reliable measure-
ment of ion intensity. Characterization of endogenously bound
peptides will to a great extent reflect which peptides generate
kinetically stable peptide-MHC II complexes. Given the im-
pact of quantity of MHC-peptide complexes for activation of
T cells, we have undertaken a comprehensive quantitative and
comparative mass spectrometric analysis of endogenous pep-
tides bound to DQ2.5, DQ2.2, and DQ7.5 molecules isolated
from a panel of nine cell lines. This should also improve our
understanding of how these DQ molecules select their pep-
tides for presentation.
Materials and methods
Cell lines and culturing
Table 1 lists the Epstein–Barr virus (EBV)-transformed B-
lymphoblastoid cell lines (B-LCLs) used in this study. The
cell lines 9087 STEINLIN, 9088 PF04015, 9047 PLH, 9050
MOU, 9051 PITOUT, 9037 SWEIG, 9064 AMALA, and
9089 BOB were obtained from the Tenth International Histo-
compatibility Workshop (http://www.ihwg.org/cellbank),
whereas the cell line CD114 was derived from a celiac disease
patient. All cell lines were grown in RPMI medium supple-
mented with 10 % FCS.
Isolation of HLA-DQ-associated peptides
The cells, 7×107 for each technical replicate, were lysed for
30 min on ice at a concentration of 108 cells/ml in PBS
containing 1 % Nonidet P-40, 5 mM sodium orthovanadate,
25 mM iodoacetamide, 1 mM PMSF, and a protease inhibitor
cocktail (complete, EDTA-free tablets; Roche Diagnostics).
The lysate was clarified by centrifugation at 15,700×g for
20 min at 4 °C, and DQ molecules were immunoprecipitated
from the supernatant using SPV-L3 (anti-DQ) (Spits et al.
1984) or 2.12.E11 (anti-DQ2) (Viken et al. 1995) covalently
cross-linked to Protein A Sepharose CL-4B. The sepharose
were then washed 10 times with 1 ml PBS containing 0.1 %
octyl glucoside, 10 times with 1 ml Milli-Q water containing
0.1 % octyl glucoside and finally three times with 1 ml Milli-
Q water. After this extensive washing, peptides were acid
eluted with 0.1 % trifluoroacetic acid at 37 °C for 5 min two
times.
Analysis by mass spectrometry
All samples were purified by reversed phase chromatography
using microcolumns prepared by placing a disk of C18
Empore Extraction Disk (Varian, St. Paul, MN, USA) into
200-μl pipet tips. Peptides were eluted by applying 60 μl of
70 % ACN and 0.1 % formic acid in water. ACN was evap-
orated in a vacuum drier, and the samples were diluted in
0.1 % formic acid in water before the peptides were analyzed
on a Dionex Ultimate 3000 nano-LC system (Dionex,
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Sunnyvale, CA, USA), which was connected to a quadrupole-
Orbitrap (QExactive) mass spectrometer (ThermoElectron,
Bremen, Germany) equipped with a nanoelectrospray ion
source (Proxeon/Thermo). An Acclaim PepMap100 RSLC
column (C18, 2 μm beads, 100 Å, 75 μm inner diameter)
(Dionex, Sunnyvale, CA, USA) of a 15-cm bed length was
used to separate the peptides. The flow rate used was 0.3 μl/
min and the solvent gradient was 5 to 50 % B in 45 min
(solvent A: 0.1 % formic acid, solvent B: 90 % ACN/0.1 %
formic acid). The mass spectrometer was operated in the data-
dependent acquisition mode using the Xcalibur 2.2 software.
Single MS full-scan in the Orbitrap (300–1750 m/z, 70,000
resolution at m/z 200, AGC target 1×106 maximum IT 20ms)
were followed by 10 data-dependent MS/MS scans in the
Orbitrap after accumulation of 1×106 ions in the C-trap or
an injection time of 120 ms at 35,000 resolution (Kelstrup
et al. 2012) (isolation width 2.0 m/z, underfill ratio 0.1 %,
dynamic exclusion 20 s) or after accumulation of 2×105 ions
in the C-trap or an injection time of 60 ms at 17,500 resolution
(isolation width 3.0 m/z, underfill ratio 0.4 %, dynamic ex-
clusion 20 s). The normalized collision energy was set to 25 or
30 %.
Peptide identification and peak volume calculation
MS raw files were submitted to MaxQuant software version
1.3.0.5 (19) using Andromeda as a search engine for peptide
and protein identification. Pyro-glu (N-term Q and N-term E),
deamidation (NQ), and oxidation (M) were set as variable
modifications, and we used a first search error window of
20 ppm and main search error of 6 ppm. No fixed modifica-
tions were used. Unspecific enzyme option was selected and
no miscleavages were allowed. Mass tolerance for fragment
ions was set to 20 ppm.Minimal unique peptides were set to 1,
and a false discovery rate of 0.01 (1 %) was used in all
instances, and maximum PEP score allowed was 0.1.
Identification of peptides was based on parent ion mass and
fragmentation spectra. For identification of peptides, retention
time alignment was used, ions that had the same parent ion
mass and which eluted with the same LC-retention time as a
peptide with identified fragmentation spectra were correlated
with an alignment window of 3 min. A human database
(downloaded from www.UniProt.org December 2013,
89,628 entries) was searched to identify peptides. We selected
for generation of contaminants and reversed sequences to
assign the presence of contamination and false discovery
rates. Quantitative information provided by MaxQuant at the
peptide level was obtained using an area under curve assign-
ment, using acquisition features such as mass width, retention
time profile, and MS1 ion scan intensity. This value was
calculated using a three-dimensional approach and represents
the ion peak volume. Peak volumes were calculated only if a
minimal of two MS counts were observed (MaxQuant de-
fault). To allow sample comparison, the data was normalized
to eliminate false-positive comparisons based on sample load-
ing variation. Therefore, for each sample, the peak volume of
each individual peptide was normalized using a scale ratio
approach where individual peptide values was divided by the
sum of the peak volumes for all identified peptides in that
same sample, which transform all individual peptide values to
a 0–1 scale. The comparison of the amounts of individual
peptides across samples was therefore relative.
Statistical analysis
The statistical tool R version 2.15.2 with the package
gplots version 2.11.0 was used to generate a heatmap.
Quantitative values obtained from MS acquisition were
used as basis for the clustering. Columns were hierar-
chical clustered with “average” as agglomeration method
and “correlation” as distance matrix. Rows were ordered
by hierarchical clustering, but with “ward” as
Table 1 EBV-transformed B-lymphoblastoid cell lines
Cell line Serological profile DNA typing profile
DR DQ DP DRB1* DRB3/B4/B5 DQA1* DQB1* DPA1* DPB1*
CD114 3 2.5 1,4 03:01 DRB3*01:01 05:01 02:01 Nd 01:01/04:01
9087 STEINLIN 3 2.5 3,4 03:01 DRB3*01:01 05:01 02:01 01 03:01/04:01
9088 PF04015 3 2.5 1,4 03:01 DRB3*01:01 05:01 02:01 01,02:01 01:01/04:01
9047 PLH 7 2.2 nd 07:01 DRB4*01:01 02:01 02:02 01:03 15:01
9050 MOU 7 2.2 2 07:01 DRB4*01:01 02:01 02:02 01:03 02:01
9051 PITOUT 7 2.2 4 07:01 DRB4*01:01 02:01 02:02 01 04:01
9037 SWEIG 11 7.5 4 11:01 DRB3*02:02 05:05 03:01 01:03 04:02
9064 AMALA 14 7.5 nd 14:02 DRB3*01:01 05:01/05:03 03:01 01:03 04:02/94:01
9089 BOB 11 7.5 4 11:04 DRB3*02:02 05:05 03:01 01 04:02
Nd not determined
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agglomeration method and “euclidean” as distance ma-
trix. To evaluate whether there were differences in the
quantitative peptide elution data between the various
DQ-types beyond what could be expected by chance,
we used two approaches. In the first approach, we
applied the method SAM (significance analysis of mi-
croarrays) (Tusher et al. 2001) to generate a Z score for
each peptide and each DQ comparison, followed by the
convest procedure of the limma R/Bioconductor package
(Langaas et al. 2005) to estimate the proportions of
peptides with a real difference between the DQ types.
In the second approach, we used the globaltest of the R/
Bioconductor package (Goeman et al. 2004) to obtain
p values for overall DQ type differences. The histo-
grams of Z scores were generated by the method locfdr
(Efron 2007).
Neural network analysis for prediction of binding motifs
Binding motifs for the DQ2.2, DQ2.5, and DQ7.5 mol-
ecules were estimated using the NetMHCIIpan-3.0
(Karosiene et al . 2013) and NNAlign methods
(Andreatta et al. 2011). When using the NetMHCIIpan-
3.0 method, sequence logos were constructed as “Shan-
non logos” from the predicted 9mer binding core of the
strongest 2000 predicted binders from a set of 200,000
random natural 15mer peptides using the Seq2Logo
method with default settings (Thomsen and Nielsen
2012). For the NNAlign method, the quantitative peptide
elution data (excluding the CLIP peptides) were used
for the analysis. Prior to applying the NNAlign method,
the quantitative abundance values were log-transformed
using the relation log(X+0.00001), where X is the quan-
titative abundance value associated with each peptide.
Next, the NNAlign method was run with settings corre-
sponding to linear rescaling, motif length of 9, Blosum
peptide encoding, 3 hidden neurons, 5 network seeds, 5-
fold cross validation without early stopping, and com-
mon motifs to remove peptide redundancy, and default
setting for all other parameters. Logos for the sequence
motifs obtained by the NNAlign method were construct-
ed as “Shannon logos” using Seq2Logo with default
settings.
Competitive peptide-binding assay
Peptide binding was measured in a competitive peptide-
binding assay as described previously (Vader et al. 2003).
Lysates of Epstein–Barr virus-transformed B-cell lines CD
114 and 9050 MOU (2×105 cells/well) were the source of
DQ2.5 and DQ2.2 molecules, respectively. Half maximal
inhibitory concentrations (IC50) were established by measur-
ing the inhibitory effect of binding of indicator peptide (biotin-
EPRAPWIEQEGPEYW; used at 0.4 μM or 0.5 μM). Two
independent 4-fold titration experiments were performed for
each peptide.
Results
Relative quantitative analysis of endogenous peptide
repertoires of HLA-DQ2.5, HLA-DQ2.2, and HLA-DQ7.5
HLA-DQ molecules were affinity purified with the anti-
DQ antibody SPV-L3 from nine EBV-transformed B-
LCLs, three cell lines for each HLA type, DQ2.5,
DQ2.2, and DQ7.5 (Table 1 and Fig. 1a). Bound pep-
tides were acid eluted and subjected to LC-MS/MS and
MaxQuant software analysis. Two experiments were
performed for each cell line, and each sample was run
in three technical replicates on the LC-MS/MS; in total,
54 samples were analyzed. The information of identified
peptides is given in Supplemental Table 1. The data
contains peptide sequence information, mass, charge,
scoring, and quantitative information. For technical rea-
sons, some experiments gave very low total peptide ion
peak volumes and these were not included in the anal-
ysis. The MaxQuant software permits estimation of pep-
tide abundance as ion peak volumes, which are based
on peptide retention time, mass accuracy, and MS ion
intensity as quantifiable parameters. Hierarchical cluster-
ing analysis of normalized quantitative data showed that
the repertoires of identified peptides were distinct for
each of the three DQ molecules, with high similarity
between cell lines of the same DQ type (Fig. 1b).
The length of the eluted peptides varied between 8 and 25
residues with a peak in distribution at 14 (Fig. 2). Most of the
eluted peptides could be assigned to nested sets of sequences.
This is in agreement with earlier reports (Chicz et al. 1993;
Lippolis et al. 2002). We identified 4267 peptides in the
eluates of DQ2.5 molecules, 7395 peptides in the eluates of
DQ2.2 molecules, and 7380 peptides in the eluates of DQ7.5
molecules. Altogether, 12,712 unique peptides were identi-
fied. The identity and quantity of peptides eluted from the
different DQ-types were highly significantly different
(globaltest results: DQ2.5 vs DQ2.2, p=9.41×10−24; DQ2.5
vs DQ7.5, p=1.82×10−24; and DQ2.2 vs DQ7.5, p=5.43×
10−31). Generating Z scores for each peptide and each DQ
comparison, we estimated the proportion of peptides with a
real difference (convest-procedure) to be the following:
DQ2.2 vs DQ2.5: 0.67, DQ2.5 vs DQ7.5: 0.72, and DQ2.2
vs DQ7.5: 0.90 (Supplemental Fig. 1). We also compared
peptides eluted from DQ2.2 molecules of the same cell line
(9050 MOU) that had been affinity purified with either the
SPV-L3 (pan DQ-specific) or 2.12.E11 (DQ2-specific) mono-
clonal antibodies. Clustering analysis showed that the peptides
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Fig. 1 Peptide elution from nine cell lines carrying DQ2.5, DQ2.2, and
DQ7.5. a Experimental setup of peptide elution experiments. b Heatmap
and dendrogram of eluted peptides from the nine cell lines carrying
DQ7.5, DQ2.5, and DQ2.2. Peptides were eluted from three cell lines
expressing DQ7.5, three cell lines expressing DQ2.5, and three cell lines
expressing DQ2.2. Two biological replicates of each cell line and three
technical replicates for each of these were run. Normalized ion peak
volumes were log transformed. The heatmap and dendrogram were
created with the statistical software R. The CLIP peptides are indicated
with short lines on the left side of the heatmap. Blue=absent. Red=log-
transformed ion peak volumes
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eluted from the HLAmolecules purified with the two different
monoclonal antibodies clustered together (data not shown).
Characteristics of endogenous peptides of HLA-DQ2.5,
HLA-DQ2.2, and HLA-DQ7.5
We found greater differences in diversity and relative abun-
dance of endogenous peptides from DQ2.2 and DQ7.5 com-
pared to DQ2.5 (Tables 2, 3, and 4; Fig. 3). This is seen by
inspecting the entire array of eluted peptides (Fig. 3 and
Supplemental Table 2), but is also apparent from looking at
the 20 most abundant peptides eluted from each molecule
(Tables 2, 3, and 4). The normalized ion peak volume repre-
sented by these 20 peptides was 52 % for DQ2.5, 23 % for
DQ2.2, and 23% for DQ7.5. For DQ2.5, 16 of the 20 peptides
were length variants of CLIP (from invariant chain/CD74),
and two peptides were length variants of a HLA class I peptide
known to be a DQ2.5 high-affinity binder (Table 2). For
DQ2.2, seven of the peptides derived from β2-microglobulin
(representing two different core sequences), five of the pep-
tides derived from serglycin, and three peptides derived from
invariant chain (CD74) of which only one were a typical CLIP
peptide (Table 3). For DQ7.5, seven of the 20 most abundant
peptides were CLIP peptides, and there were peptides derived
from transferrin receptor (five peptides with two different
sequences) and MHC class II DRα-chain (three peptides)
(Table 4).
The abundance of CLIP peptides was particularly evident
for DQ2.5. The sum of the normalized ion peak volumes of all
CLIP variants was 53 % for DQ2.5, 5 % for DQ2.2, and 12 %
for DQ7.5. DQ2.5, and DQ2.2 displayed similar sets of CLIP
peptides, but each peptide species was present at very different
ion peak volumes (Supplemental Fig. 2). Several CLIP pep-
tides were unique to DQ7.5, and some of these did not contain
the conventional CLIP1 or the alternative CLIP2 cores (Sup-
plemental Fig. 2).
Defining peptide-binding motifs from elution data with neural
network analysis
To assess the binding specificity of the DQ2.5, DQ2.2, and
DQ7.5 molecules, we subjected the quantitative values for
Fig. 2 Length distribution of eluted peptides. The number of eluted
peptides from DQ2.5 (■), DQ2.2 (▲), and DQ7.5 (▼), and their length
distribution are given
Table 2 Twenty most abundant
peptides eluted from DQ2.5 Peptide Protein Normalized ion peak volume (%)
LPKPPKPVSKMRMATPLLMQALP CD74 9.2
PKPPKPVSKMRMATPLLMQALP CD74 5.5
RMATPLLMQALPMGALPQ CD74 5.5
MATPLLMQALPMGALPQ CD74 3.4
RMATPLLMQALPMGALP CD74 2.7
KPPKPVSKMRMATPLLMQALPM CD74 2.6
EPRAPWIEQEGPEYWDRN MHC class I 2.5
MATPLLMQALPMGALP CD74 2.3
KMRMATPLLMQALPMGALPQ CD74 2.3
EPRAPWIEQEGPEYWDQE MHC class I 2.1
MRMATPLLMQALPMGALPQ CD74 2.0
MATPLLMQALPM CD74 1.8
RMATPLLMQALPM CD74 1.7
KPPKPVSKMRMATPLLMQALP CD74 1.5
RMATPLLMQALPMGAL CD74 1.5
MATPLLMQALPMGAL CD74 1.5
LPKPPKPVSKMRMATPLLMQALPM CD74 1.1
ATPLLMQALPMGALPQ CD74 1.0
SLDRNLPSDSQDLGQHGLEEDFML Serglycin 0.9
PSDSQDLGQHGLEEDFML Serglycin 0.9
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eluted peptides as listed in Supplemental Table 2 to the neural
network-based method NNAlign (Andreatta et al. 2011). The
peptide-binding motifs obtained were compared with peptide-
binding motifs predicted by the NetMHCIIpan-3.0 (Karosiene
et al. 2013) that was trained on an extensive set of experimen-
tal MHC class II peptide-binding data including peptide bind-
ing to DQ2.5 and DQ7.5, but not including peptide-binding
data to DQ2.2 (Wang et al. 2008). This latter method also
Table 3 Twenty most abundant
peptides eluted from DQ2.2 Peptide Protein Normalized ion peak volume (%)
DPSSGLGVTKQDLGPVPM CD74 1.9
SLDRNLPSDSQDLGQHGLEEDFML Serglycin 1.9
SGFHPSDIEVDLLK β2-microglobulin 1.8
LPKPPKPVSKMRMATPLLMQALP CD74 1.5
YRYDLASGATEQLPLT Sortilin-related receptor 1.3
LPSADEIYDCKVEHWG MHC class II DQA 1.2
QDLGQHGLEEDFML Serglycin 1.1
HPSDIEVDLLK β2-microglobulin 1.1
YYTEFTPTEKDEY β2-microglobulin 1.0
GFHPSDIEVDLLK β2-microglobulin 1.0
LPSDSQDLGQHGLEEDFML Serglycin 1.0
QDLGQHGLEEDFM Serglycin 1.0
YYTEFTPTEKDE β2-microglobulin 1.0
YLLYYTEFTPTEKDEY β2-microglobulin 1.0
YLLYYTEFTPTEKDE β2-microglobulin 0.9
LPSTEDVYDCRVEHWG MHC class II DRA 0.9
IDNKGIDSDASYPYK Cathepsin S 0.9
VKTLTGKTITLEVEPSDT Ubiquitin 0.8
PSDSQDLGQHGLEEDFML Serglycin 0.8
GVTKQDLGPVPM CD74 0.8
Table 4 Twenty most abundant
peptides eluted from DQ7.5 Sequence Protein Normalized ion peak volume (%)
TPLLMQALPMGALPQ CD74 2.5
ASFEAQGALANIAVDKA MHC class II DRA 1.7
NPGGYVAYSKAATVTGKL Transferrin receptor 1.7
TPLLMQALPMGALPQGP CD74 1.5
NPGGYVAYSKAATVTG Transferrin receptor 1.5
VPVPQFGGGDPADIIHD Integral membrane protein 2C 1.4
TPLLMQALPMGALPQGPM CD74 1.4
VPVPQFGGGDPADIIHDF Integral membrane protein 2C 1.3
NPGGYVAYSKAATVTGK Transferrin receptor 1.3
IPELNKVARAAAEVAGQF Transferrin receptor 1.3
ASFEAQGALANIAVDK MHC class II DRA 1.1
LPKPPKPVSKMRMATPLLMQALP CD74 1.1
VDNALQSGNSQESVTEQ Ig kappa chain C region 0.8
SFEAQGALANIAVDKA MHC class II DRA 0.7
IEKVEHSDLSFSKDWS β2-microglobulin 0.7
ATPLLMQALPMGALPQGPM CD74 0.7
ATPLLMQALPMGALPQGP CD74 0.7
IPELNKVARAAAEVAG Transferrin receptor 0.6
LMQALPMGALPQGP CD74 0.6
IEKVEHSDLSFSKD β2-microglobulin 0.6
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Fig. 3 Normalized ion peak volumes of eluted peptides from DQ2.5
(blue), DQ2.2 (red), and DQ7.5 (green). The peptides are presented
according to number and sequences as given in Supplemental Table 2.
The ion peak volumes were normalized against total ion peak volumes of
all eluted peptides for each technical replicate and are shown in
percentage (%). The average ion peak volume of all samples for each
HLA type is shown
Fig. 4 Sequence logos showing the peptide-binding motifs of DQ2.2,
DQ2.5, and DQ7.5. a Sequence logos defined byNetMHCIIpan-3.0. The
sequence logos of DQ2.5 and DQ7.5 are based on previously published
experimental data of peptide binding whereas the sequence logo of
DQ2.2 is a prediction based on extrapolation from other MHC class II
molecules characterized by experimental peptide-binding data. b Se-
quence logos defined by NNAlign using quantitative elution data as listed
in Supplemental Table 2 excluding CLIP-peptides (entries 1395–1515).
Logos were made using Seq2Logo as described in the text
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allows prediction of the binding motif of DQ2.2 even though
no peptide-binding data was available for this molecule when
the method was constructed. The results obtained by both
methods are depicted as sequence logos in Fig. 4. The
NetMHCIIpan analysis, based on previously available data,
revealed very similar peptide-binding motifs for DQ2.5 and
DQ2.2, which were different from the binding motif of DQ7.5
(Fig. 4a). By contrast, the NNAlign analysis, which was based
on the quantitative elution data provided here, revealed dis-
tinct binding motifs of DQ2.2 and DQ2.5 (Fig. 4b). As its
main characteristic, DQ2.2 has a unique binding motif with a
preference at P3 for threonine and serine and to lesser extent
for aspartate. In contrast, there is no amino acid preference
observed at P3 for DQ2.5 or DQ7.5. The binding motifs of
DQ2.5 and DQ7.5, but not that of DQ2.2, correspond very
well with the predictions obtained with the NetMHCIIpan
method. As a strong S/T anchor has not been indicated in
the binding data for any of the DQ molecules utilized to train
NetMHCIIpan, it is expected that this method does not report
the P3 S/T anchor for DQ2.2. Notably, the binding motifs of
DQ2.5 and DQ7.5 obtained by NNAlign analysis were similar
to the binding motifs reported previously for both molecules.
We also performed a NNAlign analysis on a filtered dataset of
10,661 peptides established by removing peptides with length
<11 residues and peptides not being part of nested sets. This
analysis gave almost identical binding motifs for all three
molecules (data not shown).
Substitution analysis shows the importance of serine
at position P3 of the binding frame
The importance of serine or threonine was investigated by
testing peptides with and without substitution at position P3 in
a biochemical competition assay for binding to DQ2.5 and
DQ2.2 (Fig. 5). Three peptides were tested; two newly
identified DQ2.2 gluten epitopes, DQ2.2-glia-α1 (core se-
quence QGSVQPQEL) and DQ2.2-glia-α2 (core sequence
QYSQPEQPI), and one of the DQ2.5 self-peptides identified
in this study (core sequenceYTGEDVTPQ).We found that all
peptides containing serine at position P3 bound with higher
affinity to DQ2.2 compared with alanine or glycine at the
same position (Fig. 5). The opposite tendency was seen for
binding to DQ2.5.
Discussion
We have performed a relative quantitative comparison of the
endogenous peptide repertoires of DQ2.5, DQ2.2, and DQ7.5.
DQ molecules were affinity purified from a panel of nine cell
lines with three cell lines of each DQ-type. Bound peptides
were eluted and subjected to MS for identification and quan-
tification. Large differences in normalized ion peak volumes
of distinct peptides were observed. The repertoires of peptides
were unique for each of the three DQ molecules. Notably, the
two DQ2 variants had clearly different peptide-binding mo-
tifs. This provides an explanation for why DQ2.5 and DQ2.2
celiac disease patients select distinct sets of gluten peptides for
presentation to CD4+ T cells, which again explains why the
two DQ2 variants have widely different risks for celiac
disease.
Our approach of quantitative proteomics of endogenous
HLA-bound peptide repertoires is feasible due to recent break-
throughs in MS with increase in instrument sensitivity as well
as improved software, allowing precise measurement of ion
peak volumes across different samples. We performed a large-
scale study where altogether 54 samples of nine distinct cell
lines were examined by relative comparison. Ionization inten-
sity for different peptides may vary during and across MS
sample acquisition, but this variation is fairly modest with LC
Fig. 5 Binding of peptides to DQ2.5 and DQ2.2. Peptide binding of two
DQ2.2 gluten epitopes and one DQ2.5 self-peptide with P3 substitutes
was assessed in a competitive-binding assay. The two DQ2.2 gluten
epitopes were tested with Ser to Ala susbstitutions at position P3, while
the DQ2.5-binding peptide was tested with Gly to Ser substitution at
position P3. The binding register of this peptide was predicted by the
NNAlign method, and to avoid a register shift that could confound
binding assay results, a Lys residue was introduced at position P5. Two
independent 4-fold titration experiments were performed. The results
shown are from one representative experiment
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and modern electrospray instrumentation. The same patterns
of peptides were observed for technical and biological repli-
cates as well as for samples representing the same HLA allelic
molecule of different cell lines. This strongly suggests that the
different quantitative patterns of peptides eluted of different
DQ molecules reflect differences in the peptide-binding char-
acteristics of the distinct DQ molecules.
Analysis of endogenous peptides to determine peptide-
binding specificity of MHC class II molecules has previously
been done by N-terminal pool sequencing (Falk et al. 1994;
Godkin et al. 1997; Khalil-Daher et al. 1998; Vartdal et al.
1996). In contrast to MCH class I molecules where this
approach has proven very successful due to the uniform length
of peptide ligands, the analysis is complicated by the variable
length and ragged ends of MHC class II ligands. We here
derived the binding specificity from quantitative data on sev-
eral thousand individual peptides from each HLA-DQ mole-
cule using the artificial neural network toolNNAlign. NNAlign
allows identification of the binding motifs in quantitative
peptide data sets also in situations where the peptides have
variable length. This approach has several advantages com-
pared to the pool sequencing. First and foremost, the method
is fully automated and unbiased. Second, this method returns a
model (an artificial neural network) that readily can be applied
to searches for peptides matching the binding specificity in
any protein/proteome of interest. Finally, this model produces
quantitative prediction values that are directly correlated to the
quantitative values associated with the peptides used to con-
struct the method. This latter feature is essential when apply-
ing the model to identify novel potential ligands and as guide
to prioritize any subsequent peptide selection.
The NetMHCIIpanmethod, which is based on a large body
of experimental peptide affinity binding data to a large panel
of MHC class II molecules (including DQ2.5, but not DQ2.2)
and therefore is believed to be able to predict the bindingmotif
of any MHC class II molecule, indicates that the binding
motifs of DQ2.5 and DQ2.2 are almost identical (Fig. 4a).
However, using the NNAlign method to analyze the present
quantitative peptide-DQ elution data revealed that DQ2.2 has
a unique peptide-binding motif with a preference for threonine
and serine, and to a lesser extent for aspartate, at the P3
position as the major requirement. DQ2.5 and DQ2.2 are
highly homologous molecules deviating by 10 amino acids
in the membrane distal domains of which only one residue,
DQα22, make contact with the peptide in the x-ray crystal
structure of DQ2.5 (Kim et al. 2004). Given this similarity, the
prominent distinction at P3 is remarkable. The NNAlign anal-
ysis of eluted peptides predicts similar preference at P6 and P7
for DQ2.2 and DQ2.5, whereas there are differences at the P1
and P9 positions, with indications for an anchor at P9 for
DQ2.2 and no anchor at P9 for DQ2.5. These observations
are at odds with previous reports, which have indicated that
both P1 and P9 are anchors for DQ2.5 and DQ2.2 (Johansen
et al. 1996a; Johansen et al. 1996b; Stepniak et al. 2008; van
deWal et al. 1996; van deWal et al. 1997; Vartdal et al. 1996).
The risk for celiac disease associated with DQ2.5 and
DQ2.2 is remarkably different (Margaritte-Jeannin et al.
2004; Sollid and Lie 2005). Studying gluten-reactive T
cells from DQ2.5 celiac patients with antigen-presenting
cells expressing DQ2.5 or DQ2.2, reactivity to all glu-
ten epitopes defined by DQ2.5 restricted T cells were
observed albeit with small quantitative differences (Qiao
et al. 2005; Vader et al. 2003). It was only when
antigen presenting cells were pulsed with antigen and
incubated for extended time before mixing with T cells
that qualitative differences were observed showing that
epitopes could make kinetically stable complexes with
DQ2.5 molecules but not with DQ2.2 molecules
(Fallang et al. 2009). In this setting, epitopes defined
by DQ2.5 restricted T cells were only presented by
DQ2.5- and not by DQ2.2-expressing antigen-
presenting cells. Thus, we reasoned that different gluten
epitopes would be presented in DQ2.5- vs DQ2.2-posi-
tive celiac patients. Isolating gluten-reactive T cells from
celiac disease patients expressing DQ2.2, we demon-
strated that distinct gluten epitopes were recognized by
CD4+ T cells in DQ2.5 compared to DQ2.2 celiac
patients, and the first DQ2.2 restricted epitope, DQ2.2-
glut-L1 (9-mer core region: PFSEQEQPV) was identi-
fied (Bodd et al. 2012). This epitope binds with high
kinetic stability to DQ2.2, but not to DQ2.5. The epi-
tope has a serine residue at position P3, which is
important for binding as its substitution with alanine
or glycine, but not with threonine, gives impaired bind-
ing (Bodd et al. 2012). Later, it was demonstrated that
six out of six gluten peptides, which could be enriched
for binding to DQ2.2 from complex gluten digests,
harbored a serine at position P3, and two of these
peptides (DQ2.2-glia-α1: QGSVQPQEL and DQ2.2-
glia-α2: QYSQPEQPI) were proven to be celiac disease
T-cell epitopes (Dorum et al. 2014). Thus, studies of
gluten epitopes in celiac disease strongly suggest that
DQ2.5 and DQ2.2, despite previous studies reporting
strong similarity in their peptide-binding motifs
(Johansen et al. 1996a; van de Wal et al. 1997), display
different peptides for presentation to T cells.
The polymorphism at DQα22, where DQ2.5 has a tyrosine
and DQ2.2 has a phenylalanine, was linked with the ability of
gluten epitopes to make kinetically stable complexes to
DQ2.5 (Fallang et al. 2009). The tyrosine of DQ2.5 partici-
pates in a hydrogen bond via a water molecule to the main
chain of the peptide as well as to histidine at DQα24 (Kim
et al. 2004). The phenylalanine of DQ2.2 lacks the hydroxyl
group of tyrosine and is unable to participate in this hydrogen-
bonding network. Modeling suggested that in peptides with
serine or threonine at P3, the hydroxyl group of these residues
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could hydrogen bond to histidine DQα24, which would ex-
plain why such peptides could bind stably to DQ2.2 (Bodd
et al. 2012). Our current analysis of accumulated endogenous
peptides of DQ2.2 strongly supports that serine or threonine
residues at position P3 are instrumental for stable binding of
peptides to this HLA-DQ molecule. Substitution analysis of
three peptides, two DQ2.2 gluten epitopes, and one DQ2.5
self-peptide demonstrated that peptides with serine at position
P3 bound with higher affinity to DQ2.2 than peptides with
alanine or glycine at position P3. Our findings are in line with
a previous study by van de Wal and co-workers which dem-
onstrated that substitution of the P3 glutamine residue of the
MHC class I 51–60 endogenous ligand with serine, threonine,
or aspartate led to an improved peptide binding to DQ2.2 (van
de Wal et al. 1997).
Celiac disease patients who are not DQ2.5, DQ8, or DQ2.2
carry DQ7.5 (Karell et al. 2003). It is likely that such patients,
similar to patients who are DQ2.5, DQ8, or DQ2.2 have
gluten reactive CD4+ T cells in the intestinal mucosa. How-
ever, whereas the DQ2.5, DQ8, and DQ2.2 restricted gluten
epitopes have negative-charged anchor residues (Bodd et al.
2012; Sollid et al. 2012), the binding motif of DQ7.5, which
does not include the involvement of charged residues, sug-
gests that DQ7.5 restricted gluten epitopes (if they exist) are
qualitatively different—likely without the key role of gluta-
mate residues resulting from transglutaminase 2-mediated
deamidation as seen for the gluten epitopes characterized to
date. Altogether, the peptide elution data support the notion
that the three celiac disease-associated molecules DQ2.5,
DQ2.2, and DQ7.5 have different specificity requirements
for peptide binding, which would lead to different repertoires
of HLA ligands and different amounts of gluten peptides
being presented to CD4+ T cells. This again could account
for why the three DQ variants have distinct risks for celiac
disease.
As expected, there was a dominance of CLIP peptides for
DQ2.5 with higher ion peak volumes than for CLIP peptides
eluted from DQ2.2 and DQ7.5. Correspondingly, the remain-
ing number of identified endogenous peptides for DQ2.5 was
lower than the number of endogenous peptides identified for
DQ2.2 and DQ7.5. This disproportionate representation of
individual peptide sequences is likely explained by the dom-
inance of CLIP peptides for DQ2.5. The CLIP peptides eluted
from DQ2.5 and DQ2.2 contained the conventional CLIP1
(Malcherek et al. 1995) or the alternative CLIP2 (Fallang et al.
2008;Wiesner et al. 2008) cores, or both. Interestingly, several
CLIP peptides were unique to DQ7.5, and some of these did
not contain the CLIP1 or CLIP2 cores. Possibly, DQ7.5 can
bind some CLIP peptides in yet another unique register, likely
explained by the peptide-binding specificity of this molecule.
Taken together, we here demonstrate that the three DQ
molecules associated with celiac disease, DQ2.5, DQ2.2,
and DQ7.5 display endogenous peptides that differ in
sequence and quantity. Even the highly homologous DQ2
variants, DQ2.5 and DQ2.2, differ in their peptide-binding
preference. This difference translates into selection of distinc-
tive gluten epitopes by the three DQ allotypes for presentation
to T cells in celiac disease.
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